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Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across 
different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients 
infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 
1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols 
on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of 
patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients 
analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mainly 
due to 80K presence in GT1a (17%). Almost all GTs showed high prevalence of NS5A-RASs (range: 10.2–
45.4%), and especially of 93H (5.1%). NS5A-RASs with fold-change >100x were detected in 6.8% GT1a 
(30H/R-31M-93C/H), 10.3% GT1b (31V-93H), 28.4% GT2c (28C-31M-93H), 8.5% GT3a (30K-93H), 45.5% 
GT4a (28M-30R-93H) and 3.8% GT4d (28V-30S-93H). Sofosbuvir RAS 282T was never detected, while 
the 159F and 316N RASs were found in GT1b (13.4–19.1%, respectively). Natural RASs are common in 
Italian patients infected with HCV-GTs 1–4. High prevalence of clinically-relevant RASs (such as Y93H) 
supports the appropriateness of HCV resistance-test to properly guide DAA-based therapy.
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In the last few years, the management of chronic Hepatitis C virus (HCV) infection was revolutioned by the 
introduction of new anti-HCV therapies based on direct-acting antiviral agents (DAAs). Short, highly effective 
and well tolerated interferon-free combinations of DAAs targeting three distinct non-structural HCV proteins 
(NS3–4A protease, NS5A, and NS5B polymerase) are now available for clinical use, allowing to reach outstanding 
cure rates even in patients that once were considered “difficult-to-treat”1.
Nevertheless, viral failure can still occur in a 5–10% of patients, most of which present clinical and virolog-
ical characteristics that, when combined, can reduce DAA efficacy2–4. Among virological ones, NS3 and (more 
importantly) NS5A substitutions naturally present in the infecting viral strain were shown to significantly reduce 
sustained viral response (SVR) rates to NS3-protease inhibitors (PI) and NS5A-inhibitors5–9.
Natural presence of RASs is a unique characteristic of HCV, not shared with other viruses responsible for chronic 
infections, such as HBV or HIV. It depends on the extremely high intrinsic genetic variability of HCV, consequence 
of its high mutational rate and replication turn-over, along with lack of proof-reading activity by viral polymerase.
Natural RASs are reported with highly variable prevalence across different HCV genotypes (GTs)10 but some 
of them, when present, are able to significantly reduce SVR rates to specific DAAs in complex patients (infection 
by HCV GT1a or 3, high baseline viremia, previous treatment experience, cirrhosis presence)1,5,9,11,12. Even with 
newer DAAs, for instance, patients with GT3 infection and natural RASs may more frequently experience viro-
logical failure13,14. Under these conditions, a tailored approach in some (not infrequent, though) real-life situa-
tions may help in bringing the cure rate closer to the 98–99%5,9,11,15.
Thanks to new and highly effective DAAs, HCV treatment is moving towards simpler regimens, the chances 
to use proficiency very short and ribavirin-free regimens will probably rely on a pre-selection of eligible patients, 
a selection that could likely take into account also natural resistance. So far, the natural prevalence of RASs was 
not extensively defined for some populations, such as non GT1 infected patients, patients with cirrhosis, and/or 
patients with previous IFN experience. In addition, very few reports on circulation of HCV GTs and subtypes 
in Italy are present in literature to date, as large dataset of HCV sequences were not available. A recent review of 
HCV GTs distribution in selected West European regions from 2011–2015 estimated, in Italy, a 62% prevalence 
of GT1 infection (21.8% 1a, 37.4% 1b, 2.8% not specified), 15.4% GT2, 14.9% GT3, 7.6% GT4 and 0.1% GT516.
The aim of this study was to extensively characterize the presence of natural RASs in the NS3, NS5A and NS5B 
regions of HCV, in a large clinical multicentre database from real-life clinical practice in DAA naïve patients, able 
to represent the main HCV GTs and subtypes circulating in Italy.
Results
Study population. Natural RASs were analysed in 2618 sequences from 1455 chronic HCV-infected patients 
naïve to NS3- (N = 1032), and/or NS5A- (N = 1090), and/or NS5B-inhibitors (N = 496).
Clinical and virological characteristics of the 1455 patients included are summarized in Table 1. The patients 
were aged 56 (50–66) years, and 69.6% were male; 489/1455 (33.6%) patients were IFN-naïve. Half of patients 
(55%) had a liver cirrhosis, and a minority had a history of liver transplant (4.5%) or hepatocellular carcinoma 
(HCC, 4.1%). Fibroscan value and/or Metavir score was available for 1279/1455 patients included. Of them 750 
(58.6%) had F4-cirrhosis. A small numer of patients had F0/F1 fibrosis (N = 22, 1.7%) or F2 fibrosis (N = 146, 
11.4%), while 361 had F3 fibrosis (N = 361, 28.2%). Child-Pugh was available for 213 cirrhotic patients, and of 
them only 28 had decompensated cirrhosis.
Patients with HIV and HBV coinfection were 5.2% (76/1455) and 2.7% (39/1455), respectively.
All HCV-GTs circulating in Europe were well represented, since we included 464 GT1a, 585 GT1b, 92 GT2c, 199 
GT3a, 16 GT4a and 99 GT4d samples. In addition, clinical centres collaborating in enrolling patients were distributed 
across all the Italian territory, from North to South and including also Sardinia and Sicily (see Supplementary Fig. S1).
The overall prevalence of natural RASs in at least 1 DAA target was 20.7% (301/1455).
HCV genotype and subtype
Overall1a 1b 2c 3a 4a 4d
Patients included, N 464 585 92 199 16 99 1455
Males, N(%) 381 (82.1) 317 (54.2) 51 (55.4) 171 (85.9) 14 (87.5) 79 (79.8) 1013 (69.6)
Age (years), Median (IQR) 52 (47–57) 65 (55–72) 70 (63–76) 54 (49–58) 53 (43–56) 53 (49–57) 56 (50–66)
BMI (Kg/m2), Median (IQR) 25 (22–29) 26 (24–30) 28 (23–34) 24 (22–27) 27 (27–27) 24 (22–26) 25 (23–28)
IL-28B genotypea
CC 31 (22.0) 19 (9.7) 1 (12.5) 10 (38.5) 1 (33.3) 2 (9.1) 64 (16.2)
CT 91 (64.5) 125 (64.1) 5 (62.5) 12 (46.2) 2 (66.7) 14 (63.6) 249 (63.0)
TT 19 (13.5) 51 (26.2) 2 (25.0) 4 (15.4) 0 (0.0) 6 (27.3) 82 (20.8)
Cirrhosis, N(%) 214 (46.1) 347 (59.3) 48 (52.2) 118 (59.3) 8 (50) 65 (65.7) 800 (55)
Liver transplant, N(%) 15 (3.2) 28 (4.8) 2 (2.2) 16 (8.0) 1 (6.3) 3 (3.0) 65 (4.5)
HCC, N(%) 4 (0.9) 35 (6.0) 7 (7.6) 10 (5.0) 0 (0.0) 3 (3.0) 59 (4.1)
IFN naive, N(%) 175 (37.7) 160 (27.4) 46 (50) 79 (39.7) 5 (31.3) 24 (24.2) 489 (33.6)
HBV coinfection, N(%) 19 (4.1) 10 (1.7) 0 (0.0) 9 (4.5) 1 (6.3) 0 (0.0) 39 (2.7)
HIV coinfection, N(%) 36 (7.8) 6 (1.0) 1 (1.1) 19 (9.5) 0 (0.0) 14 (14.1) 76 (5.2)
Table 1. Demographic characteristics of the study population. aAvailable for 141 GT-1a, 195 GT-1b, 8 GT-2c, 
26 GT-3a, 3 GT-4a and 22 GT-4d patients. IQR, interquartile range; BMI, body mass index; HCC, hepatocellular 
carcinoma; IFN, interferon.
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Prevalence of natural NS3, NS5A and NS5B RASs. At least 1 NS3-RAS was detected in 211/1032 
patients analyzed (20.4%). In particular, 97/1032 (9.4%) presented RASs able to confer low-level of resistance 
(fold-change < 100), and 6/1032 (0.6%) had RASs associated with intermediate levels of resistance (fold-change 
100–1000) (Table 2).
Natural NS3 RASs were mainly present in GT1a (152/336, 45.2%) and GT1b (46/427, 10.8%) (Fig. 1, panel 
A), with high prevalence of Q80K in GT1a (58/336, 17%). The Q80K was never found in GT4. Intermediate/
high level RASs D168A/E/T/V were found with a prevalence of 3% (2/62) in GT2c, and of 4.5% (3/66) in GT4d 
(Table 2).
Prevalence of NS3 RASs did not significantly differ according to previous treatment (IFN-failures vs. naïve), 
nor presence of cirrhosis (see Supplementary Fig. S2).
Natural NS5A RASs were found in 219/1090 (20.1%) patients, with higher prevalence in GT1a (33/322, 
10.2%), GT1b (129/435, 29.7%), GT2c (19/67, 28.3%), GT3a (30/177, 16.9%), GT4a (5/11, 45.4%); in GT4d the 
prevalence was low (3/78, 3.8%) (Fig. 1, panel B; and Table 3). Likely resistant NS5A substitutions were detected 
mainly in GT1b (10.3% prevalence [45/435]; L31V and Y93H), in GT2c (28.4% prevalence [19/67]; F28C, L31M, 
and Y93H), and in GT4a (45.5% prevalence [5/11]; V28M, L30R, and Y93H), while were detected with a fre-
quency of 6.8% (22/322) in GT1a (Q30H/R, L31M, Y93C/H), of 8.5% (15/177) in GT3a (A30K, Y93H), and of 
3.8% (3/78) in GT4d (M28V, R30S, Y93H).
The most common NS5A RAS across all genotypes was Y93H, with an overall prevalence of 5.1% (56/1090). 
Its prevalence was particularly high in GT1b (44/435, 10.1%) (Table 3).
Of the 1090 patients analyzed, 31 (2.8%) presented multiple NS5A RASs (Table 3). The contemporaneous 
detection of >1 NS5A RASs was more common in GT1b patients (21/435, 4.8%) and GT4a (2/11, 18.2%), but 
only few patients had >1 likely resistant NS5A RASs.
Prevalence of NS5A RASs did not significantly differ according to presence of cirrhosis, nor to treatment 
experience, (see Supplementary Fig. S3).
Among the 496 patients evaluated, natural NS5B RASs were detected exclusively in GT1a, GT1b and GT3a 
(Fig. 1, panel C; and Table 4).
GT1b showed the higher prevalence of NS5B RASs (30.1%, 63/209) (Fig. 1, panel C), mainly due to fre-
quent presence of L159F and C316N polymorphisms (13.4% and 19.1% prevalence, respectively). These two 
Natural NS3 RASs prevalence among HCV genotypes
1a,
N = 336
1b,
N = 427
2c,
N = 62
3a,
N = 130
4a,
N = 11
4d,
N = 66
Overall,
N = 1032
Patients with at 
least 1 RAS, N (%)a
Overall 152 (45.2) 46 (10.8) 2 (3.2) 6 (4.6) 1 (9.1) 4 (6.1) 211 (20.4)
Low-level RAS 74 (22.0) 15 (3.5) 2 (3.2) 4 (3.1) 0 (0.0) 2 (3.0) 97 (9.4)
Intermediate-level RAS 1 (0.3) 3 (0.7) 0 (0.0) 1 (0.8) 0 (0.0) 1 (1.5) 6 (0.6)
Specific RASs at NS3 positions, N(%)
36
V36L 14 (4.2) 8 (1.9) 1 (0.8) 23 (2.2)
V36M 4 (1.2) 4 (0.4)
43 F43L 1 (0.8) 1 (0.1)
54
T54A 1 (0.3) 1 (0.1)
T54S 12 (3.6) 8 (1.9) 1 (0.8) 1 (9.1) 2 (3.0) 24 (2.3)
55
V55A 13 (3.9) 2 (0.5) 15 (1.5)
V55I 8 (2.4) 1 (0.2) 1 (0.8) 10 (1.0)
56 Y56H 1 (0.2) 1 (0.1)
80
Q80K 58 (17.3) 5 (1.2) 2 (1.5) 65 (6.3)
Q80R 2 (0.6) 2 (0.5) 4 (0.4)
122 S122R 1 (0.3) 1 (0.1)
155 R155K 1 (0.3) 1 (0.1)
156
A156G 1 (0.2) 1 (0.1)
A156S 1 (0.2) 1 (0.1)
168
D168A 1 (0.2) 1 (0.1)
D168E 2 (0.6) 3 (0.7) 2 (3.2) 2 (3.0) 9 (0.9)
D168Q 1 (0.8) 1 (0.1)
D168T 1 (0.3) 1 (0.1)
D168V 2 (0.5) 1 (1.5) 3 (0.3)
170 V170A 2 (0.5) 2 (0.2)
Table 2. Natural NS3 resistance associated substitutions detected in patients naïve to NS3-protease inhibitors. 
aNS3 amino acid substitutions were classified according to the in vitro fold-change reduction in protease 
inhibitors activity in the specific HCV genotype. Low-level RASs (fold-change 2–100) are reported as plain text, 
while intermediate-level RASs (fold-change 100–1000) are reported in bold. RASs observed in vivo or proposed 
to be associated with resistance (no fold-change available) are reported in italics. RAS, resistance-associated 
substitution.
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Figure 1. Prevalence of natural NS3, NS5A and NS5B resistance-associated substitutions by HCV genotype and 
subtype. NS3 resistance-associated substitutions (RASs) in panel a were classified according to the in vitro fold-
change reduction in protease inhibitors activity in the specific HCV genotype. Low-level RASs were defined by 
fold-changes between 2 and 100, while intermediate-level RASs were defined by fold-change between 100 and 
1000. The overall prevalence also include RASs observed in vivo or proposed to be associated with resistance (no 
fold-change available). NS5A substitutions in panel b were divided both according to the in vitro fold-change 
reduction, and to their potential association with resistance in vivo. For 1st generation NS5A-inhibitors, RASs 
with fold-change 2.5–20× are reported as “likely susceptible”; RASs with fold-change 20–100 or only in vivo 
RAS (no fold-change available) are reported as “resistance possible”. Lastly, RASs with fold-change >100× are 
defined as “resistance likely”. For 2nd generation NS5A-inhibitors elbasvir, pibrentasvir and velpatasvir, RASs 
with fold-change <2.5× are reported as “likely susceptible”, RASs with fold-change 2.5–9 or only in vivo RAS (no 
fold-change available) are reported as “resistance possible”. Lastly, RASs with fold-change >10x are reported as 
“resistance likely”. Additional rule applied: 1 level up if found in virologic failure. NS5B substitutions in panel c 
were reported separately for dasabuvir or sofosbuvir. RAS, resistance-associated substitution.
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polymorphisms were usually found together, as also confirmed by covariation analysis (phy = 0.67, P < 0.001). 
The prevalence of both L159F and C316N tended to be higher in IFN-experienced GT1b patients (14.4% and 
20.9% respectively), than in IFN-naïve (10.5% and 14.0% respectively), though the difference was not statistically 
significant (P = 0.64 and P = 0.32 by Fisher exact test, respectively).
Prevalence of multiple natural RASs on different DAAs gene targets. Among the 372 patients who 
were tested for natural resistance on all 3 genes, 29 (7.3%) showed multiple RASs on >2 drug-targets. The most 
prevalent association was of NS3 plus NS5A RASs (10/372, 2.7%), followed by NS3 plus NS5B RASs (7/372, 1.9%), 
NS5A plus NS5B RASs (6/372, 1.6%) and NS5B-NI (nucleoside NS5B polymerase inhibitors) plus NS5B-NNI 
(non-nucleoside NS5B polymerase inhibitors) RASs (4/372, 1.1%, all GT1b) (see Supplementary Fig. S4).
Multiple RASs on 3 drug-targets were detected exclusively in 2 GT1b patients (0.5%).
Natural NS5A RASs prevalence among HCV genotypes
1a, N = 322 1b, N = 435 2c, N = 67 3a, N = 177 4a, N = 11 4d, N = 78
Overall, 
N = 1090
Patients with at 
least 1 RAS, N(%)a
Overall 33 (10.2) 129 (29.7) 19 (28.4) 30 (16.9) 5 (45.5) 3 (3.8) 219 (20.1)
Resistance likely 22 (6.8) 45 (10.3) 19 (28.4) 15 (8.5) 5 (45.5) 3 (3.8) 109 (10.0)
Resistance possible 12 (3.7) 87 (20.0) 0 (0.0) 17 (9.6) 0 (0.0) 1 (1.3) 117 (10.7)
Likely susceptible 0 (0.0) 15 (3.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 15 (1.4)
Patients with >1 
RAS, N(%)a Overall 2 (0.6) 21 (4.8) 2 (3.0) 3 (1.7) 2 (18.2) 1 (1.3) 31 (2.8)
Resistance likely 1 (0.3) 1 (0.2) 2 (3.0) 1 (0.6) 2 (18.2) 0 (0.0) 7 (0.6)
Specific RASs at NS5A positions
24
K24R 1 (0.3) 1 (0.1)
Q24K 4 (0.9) 4 (0.4)
28
F28C 17 (25.4) 17 (1.6)
L/M28V 11 (3.4) 1 (1.3) 12 (1.1)
L/V28M 15 (3.4) 3 (27.3) 18 (1.7)
30
Q30H 2 (0.6) 2 (0.2)
A30K 7 (4.0) 7 (0.6)
Q/L30R 6 (1.9) 3 (27.3) 9 (0.8)
R30Q 22 (5.1) 22 (2.0)
R30S 1 (1.3) 1 (0.1)
A30V 1 (0.6) 1 (0.1)
31
L31I 2 (0.5) 2 (0.2)
L31F 1 (0.6) 1 (0.1)
L31M 9 (2.8) 21 (4.8) 3 (4.5) 33 (3)
L31P 1 (0.6) 1 (0.1)
L/M31V 2 (0.5) 1 (1.3) 3 (0.3)
58
P58A 1 (0.2) 1 (0.1)
P58L 3 (0.7) 3 (0.3)
P58S 15 (3.4) 15 (1.4)
P58T 4 (0.9) 4 (0.4)
62 A62L 15 (8.5) 15 (1.4)
92 A92T 20 (4.6) 20 (1.8)
93
Y93C 2 (0.6) 1 (0.2) 3 (0.3)
Y93H 1 (0.3) 44 (10.1) 1 (1.5) 8 (4.5) 1 (9.1) 1 (1.3) 56 (5.1)
Y93I 1 (0.2) 1 (0.1)
Y93N 3 (0.9) 3 (0.3)
Table 3. Natural NS5A resistance associated substitutions detected in patients naïve to NS5A inhibitors. aNS5A 
amino acid substitutions were classified according to the in vitro fold-change reduction in protease inhibitors 
activity in the specific HCV genotype. For 1st generation NS5A-inhibitors, RASs with fold-change >100× are 
reported in bold and underlined (resistance likely); RASs with fold-change 20–100 or only in vivo RAS, no 
fold-change, are reported in bold (resistance possible); RASs with fold-change 2.5–20× are reported plain 
text (likely susceptible). For 2nd generation NS5A-inhibitors elbasvir, pibrentasvir and velpatasvir, RASs with 
fold-change >10× are reported in bold and underlined (resistance likely); RASs with fold-change 2.5–9 or 
only in vivo RAS, no fold-change, are reported in bold (resistance possible); RASs with fold-change <2.5× are 
reported in plain text (likely susceptible). Additional rule applied: 1 level up if found in virologic failure. RAS, 
resistance-associated substitution.
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Covariation analysis revealed a cross-target association of RASs only in patients with GT1 infection. In GT1b, 
NS5A-P58S and NS5B-V321A RASs were significantly associated (phy = 0.44, P = 0.03 by covariation analy-
sis), as well as NS3-S122A and NS5A-M28V RASs in GT1a (phy = 0.40, P = 0.04 by covariation analysis) (see 
Supplementary Fig. S5).
Discussion
Thanks to a nation-wide collaboration (Vironet C), the present study collects a large number of sequences 
from DAA-naïve patients, able to represent the circulation of HCV resistant strains in Italy. Among the 1455 
patients included in the analysis, 20.7% were infected with viral strains harboring at least one RASs in one of the 
3 DAA-targeted regions.
Across all GTs, NS5A RASs were the most frequently detected (20.1%, 219/1090), especially in GT1b (29.7%, 
129/435). A previous global study reported a much higher prevalence of RASs in GT1b (41.7%)17, but our results 
are concordant with a recent Italian study, that highlighted natural NS5A RASs in 23% (14/61) GT1b patients18. 
A smaller Italian local dataset also reported a 11.9% natural NS5A-RASs prevalence in 45 GT3 patients19, slightly 
lower than the 16.9% we found in our 177 GT3 patients.
Notably, when the analysis was limited to amino acid substitutions associated with a clinically relevant level 
or resistance (defined as “likely resistant”), their prevalence dropped to 6.8% in GT1a, 10.3% in GT1b and 8.5% 
in GT3a. In addition, “likely resistant” substitutions were found with high prevalence in GT2c patients (28.4%, 
mainly due to F28C presence), and GT4a (45.5% for L30R and V28M presence). To our knowledge, F28C essen-
tially affects the efficacy of daclatasvir in GT2a replicons in vitro (FC = 400)20, but no data are available for F28C 
in GT2c patients treated with daclatasvir or velpatasvir. However, it is interesting to note that in Italy the prev-
alence of F28C in DAA naïve population (25.4%) is much lower than that found in NS5A-failing GT2c patients 
(66.7%, 4/6; p = 0.05)21. Since GT2 patients are generally treated with short, RBV-free regimens, the role of F28C 
in treatment failure will probably deserve further attention.
Much better defined is the role of other “likely resistant” viral variants, such as those harboring substitutions at 
NS5A positions 93 and 30. In our population, the Y93H was far the most common natural NS5A-RASs detected, 
with an overall prevalence of 5.1% (56/1090), but reaching 10.1% prevalence in GT1b and 9.1% in GT4a. Recently, 
this RASs has been reported with very high prevalence also in other “rare” GT4 subtypes, such as GT4b (50%) 
and GT4r (13%)10.
The Y93H was associated with a significant drop in DAA efficacy in some HCV GTs, such as GT1a and GT3 
and clinical conditions, as presence of cirrhosis11,22,23. For instance, even though tested on a very small num-
ber of patients, the Y93H presence in GT3 IFN-experienced, DAA naïve patients reduced by 50% the efficacy 
of 12-weeks glecaprevir/pibrentasvir treatment22. In the present study, Y93H was rarely detected in both GT1a 
(0.3%) and GT3a (4.5%). This result reflects that of a recent global analysis of natural HCV RASs in 7893 subjects, 
where the Y93H was found with a prevalence of 11% in GT-1b and 6% in GT3a, while it was never detected in 
GT1a10.
In clinical trials, the presence of multiple natural NS5A RASs was associated with a further reduction in 
treatment efficacy as compared to single RASs11. The detection of multiple NS5A RASs in NS5A-naïve patients 
is quite uncommon. In our population, only 2.8% of patients (31/1090) had more than one natural NS5A RAS, 
and 0.6% (7/1090) had “likely resistant” RASs. Multiple RASs detection was more common in GT1b (4.8%), a 
GT considered easy-to-treat and thus not usually investigated for natural RASs and preferentially treated with 
short and RBV-free regimens. Nevertheless, no data are available on a possible impact of multiple NS5A RASs in 
Fold-
change
Natural NS5B RASs prevalence among 
HCV genotypes, N (%)
1a, 
N = 138
1b, 
N = 209
3a, 
N = 78
Overall, 
N = 496
Dasabuvir RASs
Patients with at least 1 
RAS, N(%) 3 (2.2) 19 (9.1) 2 (2.6) 24 (4.8)
S368T 100–1000 2 (1.4) 2 (0.4)
M414I 100–1000 1 (0.7) 1 (0.5) 2 (0.4)
E446K <100 1 (1.3) 1 (0.2)
Y448C 100–1000 1 (1.3) 1 (0.2)
S556G <100 18 (8.6) 18 (3.6)
Sofosbuvir RASs
Patients with at least 1 
RAS, N(%) 44 (21.1) 44 (8.9)
L159F <100 28 (13.4) 28 (5.6)
C316H n.a. 1 (0.5) 1 (0.2)
C316N n.a. 40 (19.1) 40 (8.1)
V321A <100 1 (0.5) 1 (0.2)
Table 4. Natural NS5B resistance associated substitutions detected in patients naïve to NS5B non nucleoside 
and nucleotide inhibitors. Mutations with >100 fold-change are reported in bold; n.a. as not available. RAS, 
resistance-associated substitution.
www.nature.com/scientificreports/
7SCiEntifiC RePoRTS |  (2018) 8:8988  | DOI:10.1038/s41598-018-26862-y
treatment efficacy for GT1b infected patients, and results obtained in GT1 up to now comes from a limited num-
ber of patients, and could be confounded by the presence of RASs with major impact even in the absence of other 
NS5A polymorphisms11. In addition, as full-length sequencing was not performed in our study, we cannot drawn 
the conclusion that individual amplicons of each region actually belong to the same virus24.
NS3 RASs were also common (20.4%, 211/1032), particularly due to their high prevalence in GT1a (45.2%, 
152/336), concordant with previous literature data17,25, and consequence of the frequent detection of Q80K 
RAS (17.3% in GT1a, 6.3% overall). Much less frequent were natural RASs at position 168, always found with a 
prevalence <5%.
Only few patients harbored specific NS5B RASs for sofosbuvir (8.9%) or dasabuvir (4.8%). As expected, the 
major RAS for sofosbuvir S282T was never detected9, while the NS5B putative RASs L159F, C316N and S556G 
were found in 13.4%, 19.1% and 8.6% GT1b patients respectively, often in association. Literature data on these 
3 RASs report very low fold-change values for sofosbuvir and dasabuvir26,27, however they have been described 
with higher prevalence in failing patients3,21,28–31, and therefore their impact is not yet completely understood.
Along with HCV sequence data, we were also able to collect clinical information, such as treatment history 
and liver status, that allowed a more in-depth characterization of the phenomenon of natural HCV drug resist-
ance. Overall, we found no significant associations among presence or absence of cirrhosis and prevalence of 
natural RASs. Similarly previous treatment with IFN-based regimens was not significantly correlated with higher 
RASs prevalence in any of the HCV-GT analyzed. However, we noticed that both L159F and C316N were more 
frequently detected in interferon/ribavirin-experienced (7% and 11% respectively) than in naïve patients (3% and 
4% respectively). The reason of this different prevalence, though not statistically significant, is unclear. Ribavirin 
is a guanosine analogue that, among the proposed mechanism of action, may directly inhibit NS5B polymerase32 
and/or promote mutagenesis33, thus potentially contribute to explain the more frequent generation and then 
selection of these substitutions in particular conditions (such as in GT1b). However, no experimental model of 
viral relapse with ribavirin are available, and the lack of clear data on ribavirin resistance makes this hypothesis 
difficult to further support.
This is one of the few studies, to our knowledge, able to assess the prevalence of patients showing contempo-
raneous presence of multiple RASs on more than 1 DAA target. Indeed, by analyzing within the 4 main HCV-GT 
circulating in Italy, we found multiclass resistance in 7.3% of patients, most frequently in GT-1b, represented by 
a combination of RASs in NS3 and in NS5A. Bartels et al. already analyzed the combinations of natural resistant 
variants across NS3, NS5A, and NS5B in GT1, and in their study they were rare, and most combinations were 
observed in a single patient34.
While the role of single-class NS3 or NS5A RASs has been discussed quite extensively, the role of multiclass 
resistance is still to be defined. Among DAAs combinations currently approved for clinical use, or soon to be, 
several involve a combination of NS3 and NS5A-inhibitors1,35–38. The excellent efficacy of these combinations in 
DAA-naïve patients makes difficult to interpret the role of multiclass resistance, even though the analysis of the 
few patients who failed to achieve HCV cure, especially with shorter regimens, may suggest a potential impact 
of double NS3 and NS5A class resistance. For instance, natural NS3 + NS5A RASs were recently observed in 
treatment-experienced GT3 patients who failed glecaprevir/pibrentasvir 12-weeks regimen22, and the presence 
of natural RASs specifically relevant for this genotype (i.e. A30K and Y93H in NS5A, ± NS3 polymorphisms) 
in this category of patients would probably require a prolongation of DAAs treatment duration to 16 weeks22. 
Similar results were highlighted in NS5A-experienced patients, in whom the presence of double-class resistance 
for glecaprevir/pibrentasvir is undoubtedly much relevant, and the impact of retreatment efficacy is higher39,40.
In conclusion, our study contributed to a better definition of the presence and circulation of resistant viral 
strains in a large Italian population of patients infected with HCV-GTs 1–4. We were able to uncover natural 
RASs presence across all HCV-GT analyzed, highlighting multiple NS5A-RASs presence in 2.8% of patients, and 
multiclass resistance in 7.3%. Clinical application of these findings remains challenging, as genotypic resistance 
testing is not available everywhere, and prescription of DAA is often limited by costs and reimbursement policies. 
Nevertheless, especially in countries with high prevalence of HCV infection and where RAS testing is available 
and validated, the knowledge of natural RASs burden in specific HCV GTs and subtypes may help focusing HCV 
diagnostic interventions in clinical conditions and settings that would maximize DAA efficacy rate, potentially 
avoiding wrong and expensive therapies.
Methods
Patients. This is an Italian multicentre, observational study involving DAA-naïve patients with chronic HCV-
infection, recruited from 23 Italian clinical centres between 2011 and 2016. A detailed description of Italian 
regions involved is included in Supplementary Fig. S1.
Eligible patients were DAA-naive who had at least one HCV genotypic resistance testing (GRT) performed 
by population sequencing on any target region (NS3, NS5A and/or NS5B) for routine clinical purposes or for 
research. Approval by ethics committee was deemed unnecessary for all patients evaluated for diagnostic purpose 
according to Italian law, because this was not an hypothesis of clinical trial on medicinal products for clinical use 
(art. 6 and art. 9, leg. decree 211/2003). In the cases evaluated only for research purpose, approval by the local 
Ethics Committees and patient written informed consent were obtained. All samples used for HCV sequencing, 
either for clinical or only research purpose, were all anonymously collected and analyzed according to Italian law 
(leg. decree 196/2003). This study was conducted in accordance with the principles of the Declaration of Helsinki. 
All information, including virological, clinical, and therapy data, were recorded in an anonymous database.
HCV Sanger sequencing. Sanger sequencing of the NS3-protease (aa 1–181), NS5A domain I (aa 1–213) 
and NS5B (aa 1–591) proteins was performed in plasma samples by using home-made protocols specific for 
each HCV genotype/subtype in 4 Italian laboratories. Overall, 93% of sequences were obtained in Tor Vergata 
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laboratory, and all laboratories who contributed with HCV sequences to the present study, recently participated 
to a nationwide validation program for HCV GRT, in which concordance in mutation detection and report 
was > 85% in all 3 genes41, thus making the possible discordance of sequencing methods marginally relevant to 
the present study. Detailed sequencing procedure is reported elsewhere21,42–45.
HCV resistance mutation analysis. Wild-type amino acids were defined according to references 
sequences from Geno2Pheno tool46.
The list of amino acid substitutions reported to confer reduced susceptibility (>2-fold increased EC50) to 
currently and soon-to-be available DAAs was defined according to published data, that also allowed the interpre-
tation and classification of clinical impact of RASs47. Details are as follows.
NS3 and NS5B RASs were classified according to fold-change reduction levels in different HCV-genotypes. 
Low-level resistance: fold-change 2–100; Intermediate-level resistance: fold-change 100–1000; High-level resist-
ance: fold-change >1000.
NS5A RASs were classified both according to the in vitro fold-change reduction, and to their potential asso-
ciation with resistance in vivo. For 1st generation NS5A-inhibitors, RASs with fold-change >100× are defined 
as resistance likely; RASs with fold-change 20–100 or only in vivo RAS (no fold-change) are defined as resistance 
possible; RASs with fold-change 2.5–20× are defined as likely susceptible. For 2nd generation NS5A-inhibitors 
elbasvir, pibrentasvir and velpatasvir, RASs with fold-change >10× are defined as resistance likely; RASs with 
fold-change 2.5–9 or only in vivo RAS (no fold-change), are defined as resistance possible; RASs with fold-change 
<2.5× are defined as likely susceptible. If RASs were found in vivo at virological failure, the level of resistance was 
increased by 1 level.
The criteria to be included in the present analysis as in vivo RASs were: a) to be found as de novo developed 
variant in failing patients in literature; or b) to have a demonstrated impact on virological response even if found 
as natural RAS in literature.
Phylogenetic analysis of NS3, NS5A and NS5B sequences. Phylogenetic analysis was performed to 
check the possibility of cross-contamination or sample mix-up during laboratory procedures, and also to evaluate 
concordance with previous subtype assignment by commercial genotyping assays.
NS3-protease, NS5A or NS5B sequences were aligned using Clustal W algorithm integrated into the BioEdit 
software. Then, all sequences were compared with reference strains of genotype 1 to 7 (GeneBank accession 
numbers: HCV-1a, M62321; HCV-1b, D90208; HCV-2a, D10988; HCV-2c, D50409; HCV-3a; HCV-4a, Y11604; 
HCV-4d, FJ462437, the same proposed by Geno2Pheno tool46) using the neighbor-joining method and the 
Kimura two-parameter distance estimation approach in MEGA v748. The reliability of the phylogenetic clustering 
was evaluated using bootstrap analysis with 1000 replicates. The significance of the group was assumed when 
bootstrap values were >70%.
Statistical analysis. Results are expressed as median values and interquartile range (IQR) for continuous 
data and number (percentage) for categorical data. Categorical variables were compared using the Chi-squared 
test and fisher’s exact test when was appropriate. All the analyses were performed using the SPSS software package 
(version 23.0) for Windows (SPSS Inc., Chicago, IL).
Mutation covariation and cluster analysis. Binomial-correlation coefficient (phi) was calculated to 
assess covariation among RASs, either on the same or on different genomic regions. Statistically significant pairs 
of RASs were identified by Fisher’s exact test, and then corrected for multiple-testing by Benjamini–Hochberg 
method (FDR = 0.05).
In order to identify and summarize higher-order interactions of RASs, we transformed the pairwise phi corre-
lation coefficients into dissimilarity values. A dendrogram was then computed by hierarchical clustering, and its 
stability was assessed from 100 bootstrap replicates.
All analyses were performed in R software.
The details of this explorative data analysis procedure have been described elsewhere49.
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